HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.

Abstract
The aim of this study was to evaluate the plasma coenzyme Q(10) (CoQ(10)) concentration, a vitamin-like substance found in every cell, which is also viewed as the most effective membrane antioxidant, of thalassemic patients and investigate the effect of chelating agents and ferritin levels on its concentration in patients with β-thalassemia major (β-TM). The study included 44 β-TM patients undergoing deferasirox (DFRA) or deferoxamine (DFO) chelation monotherapies or combined therapy with deferiprone (L1) and DFO, 20 patients with β-thalassemia (β-thal) traits and a control group of 22 healthy sex- and age-matched subjects. Complete blood counts, liver and renal function tests, lipid profiles, ferritin and plasma CoQ(10) [by high performance liquid chromatography (HPLC)] were analyzed. The mean age (14.7 ± 7.3 years; median 14.3 years) and sex (26 males, 18 females) of the β-TM patients were not statistically different from the β-thal trait patients and the control group. The plasma CoQ(10) concentration was 0.425 ± 0.136 μmol/L in β-TM patients, 0.508 ± 0.159 μmol/L in the β-thal trait patients and 0.534 ± 0.133 μmol/L in the control group. The difference was significant in both the β-TM (p < 0.001) and β-thal trait patients (p <0.05) compared to the control group. The CoQ(10) concentration was also associated with ferritin levels in β-TM patients; the β-TM patients with high ferritin levels had a lower CoQ(10) (p <0.05) concentration. Also, higher plasma CoQ(10) levels were detected in β-TM patients undergoing DFRA treatment, according to combined therapy administered (0.457 ± 0.115 vs. 0.382 ± 0.127 mg/dL respectively, p <0.05). In conclusion, both the β-thal trait and β-TM patients have lower antioxidant capacity as demonstrated by the lower CoQ(10) levels. The type of chelating agents and ferritin levels are factors effecting CoQ(10) concentration in β-TM patients.
AuthorsCigdem Karakukcu, Musa Karakukcu, Ekrem Unal, Turkan Patiroglu, Mehmet A Ozdemir, Yasemin A Torun, Peter H Tang
JournalHemoglobin (Hemoglobin) Vol. 36 Issue 3 Pg. 219-29 ( 2012) ISSN: 1532-432X [Electronic] England
PMID22483337 (Publication Type: Journal Article)
Chemical References
  • Benzoates
  • Iron Chelating Agents
  • Pyridones
  • Triazoles
  • Ubiquinone
  • Deferiprone
  • Ferritins
  • coenzyme Q10
  • Deferoxamine
  • Deferasirox
Topics
  • Adolescent
  • Adult
  • Benzoates (therapeutic use)
  • Chelation Therapy (methods)
  • Child
  • Child, Preschool
  • Deferasirox
  • Deferiprone
  • Deferoxamine (therapeutic use)
  • Drug Therapy, Combination
  • Female
  • Ferritins (blood)
  • Humans
  • Iron Chelating Agents (therapeutic use)
  • Male
  • Pyridones (therapeutic use)
  • Treatment Outcome
  • Triazoles (therapeutic use)
  • Ubiquinone (analogs & derivatives, blood)
  • Young Adult
  • beta-Thalassemia (blood, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: